Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange ...

This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband’s lead product under development ...

The Aversa™ Fentanyl patch could generate significant annual sales, estimated between $80 million to $200 million. The company focuses on developing a portfolio of transdermal products that ...

With 90% of the U.S. population living within 10 miles of a Walmart store, recalls of products they sell can have widespread ...

The FDA announced a very serious recall. A product sold in New York can cause serious, life threatening, or fatal respiratory ...

an abuse deterrent fentanyl transdermal system, with the potential to become the first and only abuse deterrent pain patch on the market. Nutriband’s AVERSA™ abuse-deterrent technology can be ...

AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl ...

Nutriband Inc. has announced an exclusive partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, which combines Nutriband's abuse-deterrent technology with Kindeva's FDA-approved ...